A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Thalidomide (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms THRiL
- 22 Sep 2017 Planned primary completion date changed from 1 May 2014 to 1 Nov 2018.
- 07 Feb 2017 Planned End Date changed from 1 May 2014 to 1 May 2019.
- 18 Apr 2011 Planned initiation date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.